SCHEMBL21247530

SCHEMBL21247530

O=C(Nc1scc(-c2cccc(Cl)c2)c1C(=O)O)c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.65
KMT2A Q03164 6/20 0.65
RAB9A P51151 1/20 0.65
NLRP3 Q96P20 1/20 0.65
GRIN2C Q14957 1/20 0.62
ANO1 Q5XXA6 11/20 0.61
PKM P14618 2/20 0.57
CASP3 P42574 1/20 0.56
SENP8 Q96LD8 1/20 0.56
SENP7 Q9BQF6 1/20 0.56
SENP6 Q9GZR1 1/20 0.56
HSP90AA1 P07900 1/20 0.54
HSP90AB1 P08238 1/20 0.54
USP2 O75604 1/20 0.54
ALDH1A1 P00352 1/20 0.54
TP53 P04637 1/20 0.54
TSHR P16473 1/20 0.54
HTT P42858 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
HSD17B10 Q99714 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3628154 0.94 ANO1 (0.66) MEN1KMT2ARAB9ANLRP3GRIN2C
SCHEMBL13819666 0.91 MEN1 (0.65) MEN1KMT2ARAB9ANLRP3GRIN2C
SCHEMBL3629742 0.91 MEN1 (0.65) MEN1KMT2ARAB9ANLRP3GRIN2C
SCHEMBL15233175 0.91 MEN1 (0.60) MEN1KMT2ARAB9ANLRP3GRIN2C
SCHEMBL4124608 0.90 CASP3 (0.72) MEN1KMT2ARAB9ANLRP3GRIN2C
SCHEMBL3628216 0.90 MEN1 (0.61) MEN1KMT2ARAB9ANLRP3GRIN2C
SCHEMBL1953916 0.89 ANO1 (0.56) MEN1KMT2ARAB9ANLRP3GRIN2C
SCHEMBL21247164 0.87 MEN1 (0.82) MEN1KMT2ARAB9ANLRP3GRIN2C
SCHEMBL13926174 0.87 ANO1 (0.72) ANO1CASP3SENP8SENP7SENP6
SCHEMBL12271278 0.86 ANO1 (0.80) MEN1KMT2ARAB9ANLRP3GRIN2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3749649-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO Pharma (FR) 2020-12-16 EP claimed
US-20200369655-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-26 US claimed
WO-2019154953-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 WO claimed
US-11840527-B2 Non-fused thiophene derivatives and their uses ENYO PHARMA (FR) 2023-12-12 US disclosed
US-11840527-B2 Non-fused thiophene derivatives and their uses ENYO PHARMA (FR) 2023-12-12 US disclosed
US-11840527-B2 Non-fused thiophene derivatives and their uses ENYO PHARMA (FR) 2023-12-12 US disclosed
EP-3749649-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO Pharma (FR) 2020-12-16 EP disclosed
US-20200369655-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-26 US disclosed
US-20200369655-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-26 US disclosed
WO-2019154953-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 WO disclosed
WO-2019154953-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369655-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES FTH1, SLC40A1, FECH MEN1 3578/4885KMT2A 3273/4885RAB9A 1953/4885
US-11840527-B2 Non-fused thiophene derivatives and their uses FTH1, SLC40A1, FECH MEN1 3578/4885KMT2A 3273/4885RAB9A 1953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.